Grace Therapeutics, Inc.
GRCE
$2.14
$0.020.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.69M | 2.59M | 1.99M | 1.96M | 2.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.38M | 3.01M | 2.45M | 2.53M | 3.09M |
| Operating Income | -2.38M | -3.01M | -2.45M | -2.53M | -3.09M |
| Income Before Tax | -15.79M | -2.88M | -2.32M | -938.00K | -3.36M |
| Income Tax Expenses | -- | -1.70M | -- | -- | -- |
| Earnings from Continuing Operations | -15.79M | -1.18M | -2.32M | -938.00K | -3.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.79M | -1.18M | -2.32M | -938.00K | -3.36M |
| EBIT | -2.38M | -3.01M | -2.45M | -2.53M | -3.09M |
| EBITDA | -2.38M | -3.01M | -2.45M | -2.53M | -3.09M |
| EPS Basic | -0.91 | -0.07 | -0.14 | -0.06 | -0.21 |
| Normalized Basic EPS | -0.08 | -0.10 | -0.09 | -0.04 | -0.13 |
| EPS Diluted | -0.91 | -0.07 | -0.14 | -0.06 | -0.21 |
| Normalized Diluted EPS | -0.08 | -0.10 | -0.09 | -0.04 | -0.13 |
| Average Basic Shares Outstanding | 17.27M | 17.26M | 16.93M | 15.92M | 15.92M |
| Average Diluted Shares Outstanding | 17.27M | 17.26M | 16.93M | 15.92M | 15.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |